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Accepted 2 January 2016Induction of apoptosis in cancer cells by therapeutic agents is an important event to detect the potential effective-
ness of therapies. Herewe explore the potential of Surface Plasmon Resonance imaging (SPRi) to assess apoptosis
in cancer cells exposed to therapeutic agents by measuring the cytochrome C release of apoptotic cells. Spots on
the SPR sensorwere coatedwith anti-cytochrome C, anti-EpCAM, anti-CD49emonoclonal antibodies and combi-
nations thereof. Cells from the breast cancer cell lineMCF7were introduced into a ﬂow cell, captured on a sensor
surface and exposed to culture mediumwith and without paclitaxel. The cells were followed for 72 h. Clear SPRi
responses were observed on the anti-EpCAM coated spots, indicating binding of theMCF7 cells with strong time
and drug presence dependent increases in SPRi responses on the spots coated with both anti-EpCAM as well as
anti-cytochrome C. This suggests a release of cytochrome C by the MCF7 cells in these speciﬁc locations. In addi-
tion ofﬂine experiments were performed where cultured MCF7 cells were exposed to complete culture medium
with paclitaxel, Trastuzumab antibody and Trastuzumab T-DM1 (an antibody drug conjugate). The supernatant
of these cells was analyzed and also their drug concentration dependent cytochrome C presence was detected.
These preliminary results suggest SPRi to be a unique tool to measure real time response of cancer cells exposed
to drugs or drug combinations.








Surface Plasmon Resonance imaging (SPRi) can be used to measure
the expression of antigens on the cell surface and antigens or proteins
secreted by cells [12,13]. In recent years a larger number of potential
therapeutic agents were identiﬁed of which only few entered into the
clinic and even fewer showed therapeutic efﬁcacy with a tolerable tox-
icity proﬁle. All drugs have in common that they ultimately have to kill
the cancer cells. These cells will undergo a process baptized apoptosis
and during this process speciﬁc alterations in the cells take place. Mea-
surement of apoptosis in cancer cells can therefore be used to screen the
effectiveness of potential therapeutic agents on cancer cell lines with
properties that can be related to the cancers to be treated [4] or to mea-
sure the response to therapy in patients [16]. A number of different
compounds are excreted during apoptosis and one such compound is
cytochrome C. Cytochrome C is a so called hemoprotein that is associat-
ed with the inner membrane of the mitochondrion where it is part of
the electron transport chain [11]. Under normal conditions cytochrome, University of Twente, Room
nds.
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. This is an open access article underC is bound to cardiolipin in the inner mitochondrial membrane. This
prevents the initiation of apoptosis. CytochromeC can becomedetached
from cardiolipin in early apoptosis by its oxidization due to the produc-
tion of mitochondrial reactive oxygen species. Cytochrome C plays an
intermediary role in early apoptosis and upon release into the cyto-
plasm it binds apoptotic protease activating factor-1 (Apaf-1) and acti-
vates caspase 9 [6], which in term starts a cascade of events with
apoptosis as the end result. As cytochrome C is highly water soluble it
can easily dissolve into the cytoplasm and disperse throughout the
cell. As apoptosis progresses cytochrome C will inevitably also leak
from the cell. This makes the detection by SPR possible.
A variety of methods are described and are commercially available.
Characteristics of apoptosis such as cell loss, nuclear morphology, DNA
content, cell membrane permeability, mitochondrial membrane poten-
tial changes and cytochrome C localization and release are measured.
However in order to detect all of these characteristics a number of com-
ponents are mixed together in a complex and laborious protocol. Mea-
surements of apoptosis are usually end point measurements and cells
cannot be followed in real time. The most commonly used techniques
to measure apoptosis are microscopy and ﬂow cytometry [1–3,7,9,14,
15,17,18]. Though robust and speciﬁc, these methods have their own
unique challenges and downsides.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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viously it was shown that SPR can be used to detect apoptosis-
associated genes [5], but this was not done using a cell sample. In a dif-
ferent study cells were brought into apoptosis and their morphological
changes were monitored using SPR [8].
Here we explored if SPR can be used to detect early apoptosis by
measurement of the apoptosismarker cytochromeC excreted in cell su-
pernatants either by collecting the supernatant after exposure to differ-
ent drugs added at different concentrations or by measuring the
response of viable cells that were captured and exposed to drugs in
real time in the SPRi instrument. In our experimentswe used a cytostat-
ic compound (Paclitaxel) a therapeutic antibody (Trastuzumab) and an
antibody drug conjugate (ADC) (Trastuzumab T-DM1), available com-
mercially as Herceptin® and Kadcyla® respectively from Genentech
inc., South San Francisco, California, USA. Detecting early apoptosis
using SPR would enable rapid therapy screening using live cells which
would further contribute towards thedevelopment of personalized can-
cer therapy.
2. Materials and methods
2.1. SPRi
For SPRi analysis an IBISMX96 SPR imager was used (IBIS Technolo-
gies BV, Enschede, The Netherlands). The height of the ﬂow cell was
300 μm enabling a homogeneous injection of cells and cell medium.
The obtained homogenous cell sample injection and larger volume of
culture medium improve the cell viability over time.
2.2. CFM spotter
For ligand immobilization on SPR sensor surfaces the Continuous
Flow Microﬂuidic (CFM) spotter was used (Wasatch Microﬂuidics LLC,
Salt Lake City, Utah, USA) [10]. Ligand immobilization buffer was used
to prime the CFM system and to dilute the desired ligands. The immobi-
lization protocol lasted 30min. The CFM spotter with a 6 × 8 print head
conﬁguration is capable of spotting up to 48 different ligands onto the
sensor in a single run simultaneously under back and forth conﬁned
ﬂow. The conﬁned back and forth ﬂow increases the efﬁciency of the
spotting and avoids the risk of evaporation for contact and non-
contact droplet based spotting methods.
2.3. SPR sensors
Easy2Spot® pre-activated G-type Senseye® sensors (Ssens BV, En-
schede, The Netherlands) were used as SPR sensor surfaces. The sensors
are delivered with a 100 nm hydrogel-like layer. This enables higher ca-
pacity coupling of ligands in the evanescent ﬁeld and gives the ligands a
level of mobility. The sensors are pre-activated for easy immobilization
without using an additional EDC–NHS activation protocol.
2.4. Antibodies
Anti-cytochrome C (Biolegend inc., San Diego, California, United
States of America) was used to capture cytochrome C, which is excreted
by the cells when they are undergoing apoptosis. Anti-Epithelial Cell
AdhesionMolecule antibody (anti-EpCAM, VU1D9) and Human epider-
mal growth factor receptor 2 antibody (anti-Her2) (both kindly provid-
ed by Immunicon, Huntingdon Valley, Philadelphia, USA) were used to
capture cells based on their cell surface molecule expression. Anti-
CD49e (BioLegend, San Diego, California, USA) was used as a negative
control as MCF7 cells do not express this marker on their cell surface.
Antibody Immunoglobulin G fragment crystallizable region (Anti-
mouse IgG Fc) (BioLegend, San Diego, California, USA) was used to cap-
ture all antibodies present in the sample.2.5. Apoptosis inducing agents
To induce apoptosis, paclitaxel (Sigma-Aldrich Chemie GmbH,
Steinheim, Germany), the therapeutic antibody Trastuzumab and the
ADC Trastuzumab T-DM1 (kindly provided by Dennis Waalboer at the
VU Amsterdam, The Netherlands) were used.
2.6. Ligand immobilization buffer
A 10 mM solution of sodium acetate (NaAc) immobilization buffer
with pH 4.5 wasmade using anhydrous sodium acetate (Sigma-Aldrich
Chemie GmbH, Steinheim, Germany) and acetic acid (Merck Schuchardt
OHG, Hohenbrunn, Germany). First a 0.2 M stock solution was made of
both components. Then from these stock solutions 1.93 parts of sodium
acetate and 3.07 parts of acetic acid were mixed and ﬁnally 95 parts of
ultrapure demineralized water were added. The pH was checked and
if needed adjusted to pH 4.5.
2.7. System buffer
As system buffer the complete cell culture medium of the MCF7 cell
line which was being analyzed was used, unless otherwise noted in the
experiment description.
2.8. Cells
The cell line thatwas used for the experimentswas the breast cancer
cell line MCF7. MCF7 is an adherent cell line. To harvest MCF7 cells a
trypsin protocol was used and the cells were resuspended in complete
culture medium (RPMI 1640 + 10% fetal calf serum +1% penicillin
streptomycin +1% L-Glutamine). RPMI 1640 was purchased from
Lonza Group Ltd., Basel, Switzerland. Fetal calf serum and penicillin
streptomycin were purchased from Sigma-Aldrich Chemie GmbH,
Steinheim, Germany.
2.9. Deactivation agent
A 1% Bovine Serum Albumin solution (BSA) (Sigma-Aldrich Chemie
GmbH, Steinheim, Germany) in sodium acetate immobilization buffer
was used as a deactivation agent. A stock solution of 2-aminoethanol
(MP Biomedicals LLC, Illkrich, France) was used to create a 100 mM 2-
aminoethanol solution with a pH of 8 and used as an extra sensor deac-
tivation step after the initial BSA deactivation.
2.10. Sensor regeneration agent
As sensor regeneration agent a 200 mM solution of H3PO4 (Sigma-
Aldrich Chemie GmbH, Steinheim, Germany)was used. Sensor regener-
ation was performed for 1 min.
2.11. Detection of cytochrome C in supernatant samples of cultures treated
with paclitaxel
To investigate if SPR is capable of detecting cytochrome C in culture
supernatant, severalﬂasks ofMCF7were culturedwith various amounts
of apoptosis inducing paclitaxel. One ﬂask was without any addition of
paclitaxel, the second had 1.5 μl (100 nM) of paclitaxel, the third had
3.0 μl (200 nM) and the last one had 6.0 μl (400 nM) added to 15 ml
of complete culture medium respectively. The ﬂasks with added pacli-
taxel were ﬁrst cultured to 80–100% conﬂuence before the compound
was added by a medium refresh. After the addition of the drugs, the
ﬂasks were cultured for another 48 h at 37 °C and 5% CO2. After these
2 days supernatants were removed from the ﬂasks. An SPR sensor was
prepared with varying spots containing: anti-cytochrome C (using a
spotting solution of 20 μg/ml antibody in ligand immobilization buffer),
anti-EpCAM as a negative control (using a spotting solution of 10 μg/ml
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gand immobilization buffer. After sensor spotting, the surface was load-
ed into the IBIS MX96 and deactivated with BSA and ethanolamine (see
deactivation agent). The program to run the IBISMX96 used association
times of 45 min per sample and after each sample the surface was re-
generated with phosphoric acid.
2.12. Detection of cytochrome C in supernatant samples of cultures treated
with paclitaxel, Trastuzumab and Trastuzumab T-DM1
In these experiments we wanted to verify if apoptosis markers can
be detected in the supernatant of cell samples that were treated with
Trastuzumab T-DM1 (an anti-Her2 based ADCwith an apoptosis induc-
ing chemical, called emtansin, attached to it), a therapeutic antibodyde-
veloped for treatment of cancers that express Her2. The chemical
compound T-DM1 is delivered to the Her2 expressing tumor cells by
binding of theHer2 antibody to the cell surface after which the attached
chemical molecule is introduced to the cell. For this experiment MCF7
cells were similarly prepared as for the paclitaxel experiments, however
in addition to paclitaxel (3.0 and 6.0 μl, which is 200 and 400nMrespec-
tively, in 15ml of complete medium) Trastuzumabwith andwithout T-
DM1 was used as an apoptosis inducing compound. The recommended
concentration for inducing apoptosis in a Her2 expressing cell line using
the T-DM1 ADC was 100 nM, as such this concentration was used for
both the T-DM1 ADC and plain variant of Trastuzumab (lacking the T-
DM1). All samples were cultured for 48 h after the addition of the apo-
ptotic agents. An SPR sensor was prepared with anti-cytochrome C
immobilized on its surface, with a concentration of 10 μg/ml. In addition
a negative control surface that was only exposed to the immobilization
buffer was used. The IBIS MX96 was programmed with an association
time of 45 min and dissociation time of 10 min each. After each of the
samples the surface was regenerated.
2.13. Real-time detection of induction of apoptosis in cell cultures exposed
to paclitaxel
To evaluate if SPRi can be used to detect apoptosis in real-time a sen-
sorwas preparedwith anti-cytochromeC spots (10 μg/ml), anti-EpCAMFig. 1. Sensorgram showing interactions of cell culture supernatant samples treatedwith variou
concentration of paclitaxel that was used in the samples is increased.spots (10 μg/ml), anti-CD49e spots (10 μg/ml) and an anti-EpCAM/anti-
Cytochrome C spot (10 μg/ml in a 50/50 ratio). The anti-CD49e spot is
used as a negative control as MCF7 cells express very low levels (if
any at all) of CD49e. The mix spot intended to capture the MCF7 cells
based on their EpCAM expression. Subsequently the mix spot was
intended to follow the anticipated apoptosis process after completeme-
dium containing paclitaxel was introduced to the captured cells. MCF7
cells were harvested from their culture ﬂask and prepared to reach a
ﬁnal cell concentration of 1.8 × 106/ml. The cells were allowed to sedi-
ment and bind to the sensor surface for 30 min. After this initial cell
binding the unbound cells were washed off and complete culturemedi-
um containing paclitaxel was ﬂushed over the sensor surface. The ﬂow
cell temperature was kept at 37 °C throughout the experiment and the
process was followed for 72 h. The same was done for an identical sep-
arate sensor, however on this sensor the cells were not exposed to pac-
litaxel, but merely to complete culture medium.
3. Results
3.1. Detection of cytochrome C in supernatant samples of cultures treated
with paclitaxel
The sensorgram of this experiment is shown in Fig. 1. The anti-
cytochromeC spot (green line) shows an increasingly higher interaction
response with increasing doses of paclitaxel used in the cell medium.
The anti-EpCAMspot shows consistent responses, with a slight decrease
in intensity for each subsequent interaction. The blank sensor surface
spot shows no interaction whatsoever with any sample, indicating
that the sensor surface by itself does not exhibit non-speciﬁc back-
ground interactions with any of the compounds in the samples.
3.2. Detection of cytochrome C in supernatant samples of cultures treated
with paclitaxel, Trastuzumab and Trastuzumab T-DM1
Fig. 2 shows the sensorgrams of supernatants of cell suspensions ex-
posed to paclitaxel, Trastuzumab or Trastuzumab T-DM1. An anti-
cytochrome C spot of 10 μg/ml (green line)was used in this experiment.
In order to be able to study the apoptotic effect of the used compoundss concentrations of paclitaxel. The response of the anti-cytochrome C spot increases as the
Fig. 2.Double referenced sensorgram showing the effect of paclitaxel and Trastuzumabwith andwithout T-DM1on the excretion of cytochrome C byMCF7 cells. The ﬁrst negative control
samplewith no apoptosis inducing agents was used for blank subtraction. The differential responses increasewhen paclitaxel, Trastuzumab and the T-DM1 ADCwere used. The responses
of the T-DM1 ADC and paclitaxel are larger, implying an increase in apoptosis in these cell samples.
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sometimes referred to as double referencing in the SPR realm. In es-
sence, thismeans that the RU values of a negative sample are subtracted
from each of the subsequent (presumably positive) samples, whichFig. 3. Sensorgram showing a real-time detection of apoptosis in cells exposed to paclitaxel. At t
EpCAM/anti-cytochrome C mix spot shows the highest response indicating that cytochrome C
reﬂectivity image of MCF7 cells at the beginning of their exposure to paclitaxel, insert B shows t
and B.were already referenced using a negative control surface. This way
any background or non-speciﬁc signals are removed from the resulting
output and only the cleaned up speciﬁc differential signal remains. The
ﬁrst sample which had no apoptosis inducing compounds added to the=0 bound cells are exposed to complete culture medium containing paclitaxel. The anti-
is actively excreted by the cells and is being bound on the surface. Insert A shows the SPR
he cells at the end of the experiment and insert C shows the differential image of inserts A
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therefore this differential signal is zero. The samples treated with pacli-
taxel show more intense interactions on the anti-cytochrome C spot
similar to those observed in Fig. 1. The samplewith Trastuzumab lacking
the T-DM1 only showed a small differential signal as compared to the
control sample whereas the differential response of the sample with
Trastuzumab T-DMI showed a similar response as the paclitaxel treated
samples. These results indicate the presence and release of cytochrome
C in the culturemediumofMCF7 cells,which increases after the cells are
exposed to Trastuzumab, Trastuzumab T-DM1 or paclitaxel suggesting
an increase in apoptosis. The blank sensor surface (purple line) shows
no differential signal. The cytochrome C spots show a slight bulk shift
when association and dissociation is initiated. This is due to the refrac-
tive index differences between the sample and the system buffer.
3.3. Real-time detection of induction of apoptosis in cell cultures exposed to
paclitaxel
Fig. 3 shows the SPRi response of cells captured on an SPRi sensor
and subsequently exposed to paclitaxel. No response is observed on
the spots coatedwith anti-CD49e, anti-cytochromeC or coupling buffer.
This indicates that MCF7 cells do not bind to these spots and therefore
no cytochrome C release can be detected. The anti-EpCAM spot shows
a rapid response that remains relatively constant over a period of
60 h. This demonstrates binding and continuous interaction of the
MCF7 cells to the anti-EpCAM present on the spot. The largest response
is observed on the anti-EpCAM/anti-cytochrome Cmix spot showing an
almost immediate drastic increase in RU after the bound cells were ex-
posed to complete culture medium containing paclitaxel. After ~18 h of
exposure to paclitaxel a sudden increase can be seen in the sensorgram
that reaches a peak at ~21 h after which it slowly decreases to a level
close to that observed for the anti-EpCAM spot.
Fig. 4 shows a different passage of MCF7 cells that were followed
similarly, however here the cellswere only exposed to complete culture
medium that did not contain paclitaxel. Similar to the experimentFig. 4. Sensorgram showing ameasurement ofMCF7 cells that were exposed to culturemedium
line), anti-cytochrome C (green line), anti-EpCAM (red line) and a mix of anti-EpCAM and anti-
and the anti-EpCAM/anti-cytochrome Cmix spot, indicating that the interaction seen here is a c
and there is no detection of apoptosis related cytochrome C.illustrated in Fig. 3 no response is observed on the spots coated with
anti-CD49e, anti-cytochrome C or coupling buffer. The SPRi response
of the anti-EpCAM/anti-cytochrome C spot showed an immediate in-
crease, the slope of this response decreased after ~42 h and was lower
as compared to the anti-EpCAM spot after this time. The SPRi response
of the anti-EpCAM spot only started after ~4 h with a similar slope as
the anti-EpCAM/anti-cytochrome C spot also here after ~42 h the
slope decreased but to a lesser extent as compared to the mixed spot.
We have previously described this phenomenon and contributed it to
cells that keep interacting with the surface and their adherent nature,
which contributes to the continuously increasing signal [12].
4. Discussion
We explored whether SPRi could be used to follow apoptosis of cells
by measuring the cytochrome C release as a progression marker of the
apoptotic process. Before conducting real time cell measurements we
harvested the culturemediumofMCF7 cells exposed for twodays to dif-
ferent concentrations of paclitaxel and showed an SPRi response on
anti-cytochrome C spots. Cytochrome C was detected in cells not ex-
posed to paclitaxel indicating the natural apoptosis of cells in culture
and with increasing doses of paclitaxel Cytochrome C release increased
(see Fig. 1). Unexpectedly SPRi responses were also observed on anti-
EpCAM spots that were intended as negative controls. As MCF7 ex-
presses EpCAMon their cell surface a possible explanation for the inter-
actions could be that during the apoptosis process the MCF7 cells
excreted vesicles in the supernatant. These vesicles have the potential
to express similarmarkers as its cell of origin, but also have the capabil-
ity to be distinct from their origin [19] and therefore can be the reason
for the interactions seen on the EpCAM spots. To exclude nonspeciﬁc
binding a separate experiment was conducted in which no cells were
added to the RPMI 1640 complete culture medium with paclitaxel
(data not shown). Except for a large bulk refractive index shift in the
raw data, no interaction was detected, indicating that the presence of
the MCF7 cells during culture was responsible for the SPRi responsewithout paclitaxel on spots coatedwith coupling buffer (purple line), anti-CD49e (yellow
cytochrome C (light green line). The cells show similar responses on both the anti-EpCAM
ontinuation of their binding interactionwith the ligands immobilized on the sensor surface
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that indeed we are detecting the apoptosis speciﬁc cytochrome C high
response values up to 14,000 RU as well as EpCAM but the SPRi re-
sponses of the latter did not increase with increasing concentrations
of paclitaxel.
To assess whether cytochrome C release could also be detected in
the supernatant of cells exposed to different therapeutic agents, the
MCF7 cells expressing Her2 were treated with drugs targeting this re-
ceptor (Trastuzumab with and without T-DM1). The responses shown
in Fig. 2 show similarities with the responses observed in Fig. 1. Again
the paclitaxel treated samples show increased interaction levels with
the anti-cytochrome C spots. The sample treated with Trastuzumab
without the T-DM1 conjugate shows a lower interaction level. This
might be explained by the action of Trastuzumab, when it binds to the
HER2 expressing cell, it reduces cancer cell proliferation by arresting
the cells in the G1 phase of the cell cycle. The T-DM1 ADC showed in-
creased interaction levels just like the paclitaxel sample. This shows
that we can indeed observe a difference between the Trastuzumab
ADC with added therapeutic/cell toxic component emtansin (T-DM1)
and Trastuzumab without such a component. The SPR sensorgrams
imply that indeed we can see a difference in the quantitative cyto-
chrome C response and that using this principle it might be possible to
study therapeutic alternatives and their effectiveness. However, if we
want to use the SPRi platform as away to analyze effects of therapeutics
directly on the cells, the cells and excreted products should be followed
in real time during exposure to the drugs. Thiswas performed in the ex-
periments illustrated in Figs. 3 and 4. Here we immobilized anti-CD49e,
anti-cytochrome C, anti-EpCAM and anti-EpCAM/cytochrome C on the
sensor surface. The mix anti-EpCAM/cytochrome C spots can capture
theMCF7 cells on the SPRi sensor as these cells have EpCAM expression
as described earlier [12]. The anti-cytochromeC part of themix spotwas
intended to detect release of cytochrome C from the cells that would
progress into apoptosis. Fig. 3 indeed shows a great difference in re-
sponses between the spots. The largest and most obvious response up
to levels of 14,000 RU indeed comes from the anti-EpCAM/
cytochrome C mix spots after the medium with paclitaxel was added.
In addition a peak is seen at around 25 h after paclitaxel addition. One
explanation is that the cells around this time pointmassively release cy-
tochrome C. Afterwards there is a decrease in intensity visible, which
may be explained by the start of the disintegration of the cells, which
detach from the sensor surface and the cytochrome C that possibly dis-
sociates from the mix spots into themedium. A decrease is also seen on
the anti-EpCAM spot but to a lesser extent. The intensities in signal are
also remarkably different, themix spot in Fig. 3 shows amuchhigher re-
sponse compared to the anti-EpCAM spot. Already after about 1 h con-
siderable intensity differences of several thousands of RU between the 2
spots can be seen. Insert A of Fig. 3 shows the MCF7 cells at the begin-
ning of their exposure to paclitaxel, insert B shows the cells at the end
of the experiment and insert C shows the differential image of inserts
A and B. It is clearly visible that in insert C the cells have underwent
morphological changes and seemingly binding of some sort has oc-
curred adjacent to them. Based on the sensorgrams we assume the
slight halos around the cells to be cytochrome C that was excreted
throughout the experiment, we have previously described a similar
“halo effect” [13]. In the control experiment seen in Fig. 4 the anti-
EpCAM and mix spots remain largely similar throughout the experi-
ment. This real time experiment could in the future be used to screen
potential therapeutic agents on live cells and follow the process to see
if they can induce apoptosis. The control experiment shown in Fig. 4,
was done in order to see what would happen with the same cells
(MCF7 of a different passage) when they are not stimulated to go into
apoptosis. This shows that cells merely continuously interact with
their ligands on the sensor surface but to a lesser extent up to 1000
RU after 40 h, a phenomenon we also described previously [12]. We as-
sume that on top of the interaction with the ligands on the sensor sur-
face the cells also exhibit their adherent properties. As they are beingmonitored using complete culture medium as a system buffer and at a
temperature of 37 °C, the cells are most likely spreading generating
higher SPR-signals while they are bound to the sensor surface. Cell-
spreading is a behavior they also exhibit in culture ﬂasks. Responses of
the anti-EpCAM and the anti-EpCAM/anti-cytochrome C mix spots
seem similar and therefore no apoptosis was detected, which agrees
with the intended circumstances of the assay. In addition in both Figs.
3 and 4 the negative control spots (anti-CD49e, anti-cytochrome C
and coupling buffer) show no interaction whatsoever as opposed to
Fig. 1, where the anti-CD49e spot shows a small interaction. Earlier in
the discussion we already mentioned that in the supernatant sample
vesicles might have been present explaining the interactions seen in
Fig. 1. These interactions did not occur in Figs. 3 and 4 as the cells that
were bound locally on the mix and anti-EpCAM spots were too few in
number to cause the sample to become saturated with vesicles and if
any vesicles were formed they would have (re)bound locally after for-
mation on the mix and anti-EpCAM spots.
5. Conclusion
SPRi can be used to detect apoptosis through measurement of cyto-
chromeC excretion. Thiswas achieved through binding of cytochromeC
to an SPR sensor coated with antibodies recognizing cytochrome C. Ex-
periments were conducted with supernatants of cells of the MCF7
breast cancer cell line exposed to cell culture medium with or without
paclitaxel, Trastuzumab or Trastuzumab T-DM1 that were introduced
in the SPRi instrument. The largest SPRi responses were observed on
spots coated with anti-cytochrome C indicating that Cytochrome C re-
lease is a relevant biomarker of apoptosis progression. In addition, living
MCF7 cells were introduced into the SPRi instrument and exposed to
cell culture mediumwith or without paclitaxel and high SPRi responses
were observed on the anti-EpCAM and anti-EpCAM/anti-cytochrome C
coated spots, demonstrating that the apoptotic process can be moni-
tored in real-time and without the use of traditional ﬂuorescent labels
or stains.
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